Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents

Blood

Volumn 101, Issue 10, 2003, Pages 4098-4104

  Zhou, Yan ^b   Hileman, Elizabeth O ^b   Plunkett, William ^b   Keating, Michael J ^b   Huang, Peng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; FREE RADICAL; REACTIVE OXYGEN METABOLITE; 2-METHOXYESTRADIOL; DRUG DERIVATIVE; ESTRADIOL; SCAVENGER; SUPEROXIDE;

ANTILEUKEMIA ACTIVITY; ARTICLE; CELL DEATH; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INFORMED CONSENT; LEUKEMIA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; ESTRADIOL; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; REACTIVE OXYGEN SPECIES; SUPEROXIDES; TUMOR CELLS, CULTURED;

EID: 0037926836     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2512     Document Type: Article

References (61)

1. Gelbke HP, Knuppen R. The excretion of five different 2-hydroxyoestrogen monomethyl ethers in human pregnancy urine. J Ster Biochem. 1976;7:457-463.
2. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A. 1994;91:3964-3968.
3. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994;368:237-239.
4. Attalla H, Makela TP, Adlercreutz H, Anderson LC. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun. 1996;228:467-473.
5. Kataoka M, Schumacher G, Cristiano RJ, et al. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo, Cancer Res. 1998;58:4761-4765.
6. Reiser F, Bernas M, Witte M, Witte C. Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Proc Soc Exp Biol Med. 1998;219:211-216.
7. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res. 1999;5:493-499.
8. Pribluda VS, Gubish ER, LaValle TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000;19:173-179.
9. Kinuya S, Kawashima A, Yokoyama K, et al. Antiangiogenic therapy and radioimmuno-therapy in colon cancer xenografts. Eur J Nucl Med. 2001;28:1306-1312.
10. Huang P, Feng L, Hileman EO, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000;407:390-395.
11. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997;51:951-962.
12. Banerjeei SK, Zoubine MN, Sarkar DK, Weston AP, Shah JH, Campbell DR. 2-Methoxy-estradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor. Anticancer Res. 2000;20:2641-2645.
13. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem. 1995;38:2041-2049.
14. Attalla H, Makela TP, Adlercreutz H, Anderson LC. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun. 1996;228:467-473.
15. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57:81-86.
16. Verdier-Pinard P, Wang Z, MohanakrishnanAK, Cushman M, Hamel E. A steroid derivative with paclitaxel-like effects on tubulin polymerization. Mol Pharmacol. 2000;57:568-575.
17. Brueggemeier RW, Bhat AS, Lovely CJ, et al. 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. J Steroid Biochem Mol Biol. 2001;78:145-156.
18. Kumar AP, Garcia GE, Slaga TJ. 2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog. 2001;31:111-124.
19. Lin HL, Liu TY, Wu CW, Chi CW. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer. 2001;92:500-509.
20. Qadan LR, Perez-Stable CM, Anderson C, et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun. 2001;285:1259-1266.
21. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol. 2001;127:405-410.
22. Seegers JC, Lottering M, Grobler CJS, et al. The mammalian metabolite, 2-methoxyestradiol, affects p53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol. 1997;62;253-267.
23. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene. 1997;14:379-384.
24. Mukhopadhyay T, Roth JA. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene. 1998;17:241-246.
25. Kataoka M, Schumacher G, Cristiano RJ, Atkinson EN, Roth JA, Mukhopadhyay T. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res. 1998;58:4761-4765.
26. Wang SH, Myc A, Koenig RJ, Bretz JD, Arscott PL, Baker JR. 2-Methoxyestradiol, an endo-genous estrogen metabolite, induces thyroid cell apoptosis. Mol Cell Endocrinol. 2000;165:163-172.
27. Kumar AP, Garcia GE, Slaga TJ. 2-methoxyestradiol blocks cell-cycle progression at G2/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog. 2001;31:111-124.
28. Maran A, Zhang M, Kennedy AM, et al. 2-methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone. 2002;30:393-398.
29. Wood L, Leese MR, Leblond B, et al. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. Anticancer Drug Des. 2001;16:209-215.
30. Devi GS, Prasad MH, Saraswathi I, Raghu D, Rao DN, Reddy PP. Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias. Clin Chim Acta. 2000;293;53-62.
31. Hileman EO, Achanta G, Huang P. Superoxide dismutase: an emerging chemotherapeutic target. Expert Opin Ther Targets. 2001;5:697-710.
32. Ivanova R, Lepage V, Loste MN, et al. Mitochondrial DNA sequence variation in human leukemic cells. Int J Cancer. 1998;76:495-498.
33. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochonddal DNA mutations in tumors and bodily fluids. Science. 2000;287:2017-2019.
34. Tan DJ, Bai RK, Wong LJ. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 2002;62:972-976.
35. Miyazono F, Schneider PM, Metzger R, et al. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus. Oncogene. 2002;21:3780-3783.
36. Singh KK, Russell J, Sigala B, Zhang Y, Williams J, Keshav KF. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene. 1999;18:6641-6646.
37. Wang TS, Kuo CF, Jan KY, Huang H. Arsenite induces apoptosis in chinese hamster ovary cells by generation of reactive oxygen species. J Cell Physiol. 1996;169:256-268.
38. Chen Y-C, Lin-Shiau S-Y, Lin J-K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol. 1998;177:324-333.
39. 2+-dependent production of superoxide. Int J Cancer. 2001;92:518-526.
40. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood. 1996;88:1052-1061.
41. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
42. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 1998;90:124-133.
43. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324.
44. Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist. 2002;7(suppl 1):14-19.
45. Huang P, Sandoval A, Van Den NE, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 2000;14:1405-1413.
46. Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2′-deoxy-2′-(fluoromethylene) cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol. 2001;61:222-229.
47. Fujimura M, Morita-Fujimura Y, Kawase M, et al. Manganese superoxide dismutase mediates the early release of mitochondrial cytochrome C and subsequent DNA fragmentation after permanent focal cerebral ischemia in mice. J Neurosci. 1999;19:3414-3422.
48. Zhang DX, Zou AP, Li PL. Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries. Circ Res. 2001;88:824-831.
49. Robertson LE, Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leuk Lymphoma. 1993;11(suppl 2):71-74.
50. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood. 1993;81:143-150.
51. Chou TC, Hayball MP. CalcuSyn: window software for dose effect analysis. Cambridge, United Kingdom: Biosoft; 1996.
52. Beyer R. An analysis of the role of coenzyme Q in free radical generation and as an oxidant. Biochem Cell Biol. 1991;70:390-343.
53. Boveris A, Chance B. Mitochondrial production of superoxide radical and hydrogen peroxide. In: Reivich M, Coburn R, Lahiri S, Chance B, eds. Tissue Hypoxia and Ischemia. New York: Plenum Press; 1997:67-82.
54. Du G, Mouithys-Mickalad A, Sluse-Goffart CM, Droy-Lefaix MT, Sluse FE. Generation of superoxide anion by mitochondria and impairment of their functions during anoxia and reoxygenation in vitro. Free Radic Biol Med. 1998;25:1066-1074.
55. Sankarapandi S, Zweier JL. Evidence against the generation of free hydroxyl radicals from the interaction of copper, zinc superoxide dismutase and hydrogen peroxide. J Biol Chem. 1999;274:34576-34583.
56. Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci. 1998;854:328-335.
57. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 3rd ed. Oxford, United Kingdom: Oxford University Press; 1999.
58. Staniek K, Gille L, Kozlov AV, Nohl H. Mitochondrial superoxide radical formation is controlled by electron bifurcation to the high and low potential pathways. Free Radic Res. 2002;36:381-387.
59. Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides. Mutation Res. 1989;210:291-301.
60. Sanderson BJ, Shield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res. 996;355:41-57.
61. Jing Y, Dai J, Chalmers-Redman RME, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102-2111.